Biggest News Aggregation in the World
📰 Hakari News

Page 9 - Hakari News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Hakari. Real-time updates on events, politics, business and more.

Akari Therapeutics Plc: Poland and U.K. Regulatory Authorities - URPL and MHRA - Approve Use of New, Higher-Yielding Manufacturing Process for Nomacopan in Pivotal Clinical Study

Third generation drug substance manufacturing process increases the final yield of nomacopan by at least 5-fold, improving cost efficiencies in the continuing Phase 3 clinical trial of nomacopan in pediatric
City Of United Kingdom Mike Moyer Eliza Schleifstein Rachelle Jacques Akari Therapeutics Plc Nasdaq

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Akari Therapeutics Plc: Akari Therapeutics Announces Presentation of a Case Study from Phase 3 Part A Clinical Trial of Nomacopan in Pediatric HSCT-TMA as a Late-Breaker at The Transplantation & Cellular Therapy Tandem Meetings

NEW YORK and LONDON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases
United States United Kingdom City Of Dennis Riedl Mike Moyer Eliza Schleifstein

Akari Therapeutics Plc: Akari Therapeutics Announces Pre-Clinical Development Progress Toward Potential IND on Long-Acting PAS-Nomacopan for Geographic Atrophy (GA)

Akari is targeting an Investigational New Drug (IND) application submission to the U.S. Food and Drug Administration in the first half of 2024Composition of matter patent application filed on long-acting
City Of United Kingdom Dennis Riedl Mike Moyer Eliza Schleifstein Elias Reichel

Akari Therapeutics Plc: Akari Therapeutics Announces Acceleration of the Phase 3 Clinical Trial of Nomacopan for Treatment of Pediatric HSCT-TMA into Pivotal Part B and Addition of a New Pipeline Program Developing Nomacopan for HSCT-TMA in Adults

Based on Type C guidance requested and received from the U.S. Food and Drug Administration (FDA), Akari announces it is moving forward into design and planning for pivotal Part B of the Phase 3 clinical
City Of United Kingdom John Neylan Mike Moyer Eliza Schleifstein Exchange Commission

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science